|
|
10th
International Inter University Scientific Meeting
Academy of Studenica
PERSPECTIVES
IN MELANOMA MANAGEMENT
& NANOTECHNOLOGY IN BIOMEDICINE
Organizers:
Institute of Oncology
Sremska Kamenica; Union of Cancer Prevention
Societies of Vojvodina, Novi Sad; Clinic of Oncology, Nis; Institute
for Oncology and Radiology of Serbia, Belgrade Center for Bioengineering,
Faculty of Mechanical Engineering, University of Belgrade
President:
Vladimir Baltic Vice-presidents: Zlata
Janjic, Radan Dzodic, Borislava Nikolin; Djuro Koruga
|
|
|
| |
HISTOPATHOLOGY
OF MALIGNANT MELANOMA
Krstić
M, Aleksić Č, *Trenkić M, Katić K, **Lukić N.
Institute
of Pathology, Medical Faculty Niš, Niš,
Serbia and Montenegro
* Clinic of Oftamology, Clinical Center Niš, Niš,
Serbia and Montenegro
** Clinic of Oncology, Clinical Center Niš, Niš,
Serbia and Montenegro
|
|
| |
ABSTRACT
Malignant
melanoma is considered "the great histologic mimic" since it may
exhibit a wide variety of histological patterns, mimicking any kind
of tumor including sarcomas, carcinomas, lymphomas, plasmocytomas,
germinal and neuroblastic tumors. Pathology request forms must be
accurately completed and give full identification details. The whole
lesion should be adequately sampled, probably by serial transverse
slicing of the biopsy at approximately 2-MM intervals, processing
all of the slices and examining sections cut at three levels. The
pathologist's report should include the following minimum data:
the site of the tumour; the type of surgical procedure; a full description
of the macroscopic appearance of the tumour, and the dimensions
of the specimen in millimeters; a statement of whether the lesion
is primary, locally recurrent or metastatic to the site; whether
there is ulceration; the Breslow thickness of the tumour; the depth
of penetration of the dermis (Clark's level) may also be stated;
the presence of radial growth phase tumour alone or vertical growth
phase; frequency of mitotic figures; the presence or absence of
tumour regression; the presence or absence of a lymphocytic inflammatory
infiltrate in, or in renspose to, the tumour (level II); the presence
of any obvious limphatic or vascular invasion or perineural invasion;
the histogenetic type of melanoma; the presence of microsatellites;
whether excision is complete/not complete; pathological staging
(TNM). The pointed out pathologist's report will help develop novel
strategies to the therapy of malignant melanoma. |
-
|
|
